191 related articles for article (PubMed ID: 31536751)
1. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
[TBL] [Abstract][Full Text] [Related]
3. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.
Gomes S; Bosco B; Loureiro JB; Ramos H; Raimundo L; Soares J; Nazareth N; Barcherini V; Domingues L; Oliveira C; Bisio A; Piazza S; Bauer MR; Brás JP; Almeida MI; Gomes C; Reis F; Fersht AR; Inga A; Santos MMM; Saraiva L
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31405179
[TBL] [Abstract][Full Text] [Related]
4. SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner.
Ramos H; Calheiros J; Almeida J; Barcherini V; Santos S; Carvalho ATP; Santos MMM; Saraiva L
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963392
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis.
Loureiro JB; Ribeiro R; Nazareth N; Ferreira T; Lopes EA; Gama A; Machuqueiro M; Alves MG; Marabini L; Oliveira PA; Santos MMM; Saraiva L
Pharmacol Res; 2022 Jan; 175():106026. PubMed ID: 34890775
[TBL] [Abstract][Full Text] [Related]
6. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
7. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
8. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.
Aggarwal M; Saxena R; Sinclair E; Fu Y; Jacobs A; Dyba M; Wang X; Cruz I; Berry D; Kallakury B; Mueller SC; Agostino SD; Blandino G; Avantaggiati ML; Chung FL
Cell Death Differ; 2016 Oct; 23(10):1615-27. PubMed ID: 27258787
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
11. A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
Ramos H; Soares MIL; Silva J; Raimundo L; Calheiros J; Gomes C; Reis F; Monteiro FA; Nunes C; Reis S; Bosco B; Piazza S; Domingues L; Chlapek P; Vlcek P; Fabian P; Rajado AT; Carvalho ATP; Veselska R; Inga A; Pinho E Melo TMVD; Saraiva L
Cell Rep; 2021 Apr; 35(2):108982. PubMed ID: 33852837
[TBL] [Abstract][Full Text] [Related]
12. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
13. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance.
Loureiro JB; Raimundo L; Calheiros J; Carvalho C; Barcherini V; Lima NR; Gomes C; Almeida MI; Alves MG; Costa JL; Santos MMM; Saraiva L
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916029
[TBL] [Abstract][Full Text] [Related]
14. Gambogic acid counteracts mutant p53 stability by inducing autophagy.
Foggetti G; Ottaggio L; Russo D; Monti P; Degan P; Fronza G; Menichini P
Biochim Biophys Acta Mol Cell Res; 2017 Feb; 1864(2):382-392. PubMed ID: 27899303
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
[TBL] [Abstract][Full Text] [Related]
16. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
18. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
[TBL] [Abstract][Full Text] [Related]
19. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
20. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]